These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 37801804)

  • 21. Effect of reductions in opioid prescribing on opioid use disorder and fatal overdose in the United States: a dynamic Markov model.
    Alexander GC; Ballreich J; Mansour O; Dowdy DW
    Addiction; 2022 Apr; 117(4):969-976. PubMed ID: 34590369
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Intervention in an opioid overdose event increases interest in treatment among individuals with opioid use disorder.
    Jones JD; Campbell AN; Brandt L; Castillo F; Abbott R; Comer SD
    Subst Abus; 2021; 42(4):407-411. PubMed ID: 32814002
    [No Abstract]   [Full Text] [Related]  

  • 23. Non-fatal opioid overdose, naloxone access, and naloxone training among people who recently used opioids or received opioid agonist treatment in Australia: The ETHOS Engage study.
    Conway A; Valerio H; Peacock A; Degenhardt L; Hayllar J; Harrod ME; Henderson C; Read P; Gilliver R; Christmass M; Dunlop A; Montebello M; Whitton G; Reid D; Lam T; Alavi M; Silk D; Marshall AD; Treloar C; Dore GJ; Grebely J;
    Int J Drug Policy; 2021 Oct; 96():103421. PubMed ID: 34452808
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Opioid overdose and inpatient care for substance use disorder care in Massachusetts.
    Morgan JR; Wang J; Barocas JA; Jaeger JL; Durham NN; Babakhanlou-Chase H; Bharel M; Walley AY; Linas BP
    J Subst Abuse Treat; 2020 May; 112():42-48. PubMed ID: 32199545
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Preliminary effectiveness of online opioid overdose and naloxone administration training and impact of naloxone possession on opioid use.
    Sisson ML; Azuero A; Chichester KR; Carpenter MJ; Businelle MS; Shelton RC; Cropsey KL
    Drug Alcohol Depend; 2023 Aug; 249():110815. PubMed ID: 37336007
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prescribing Characteristics Associated With Opioid Overdose Following Buprenorphine Taper.
    Bozinoff N; Men S; Kurdyak P; Selby P; Gomes T
    JAMA Netw Open; 2022 Sep; 5(9):e2234168. PubMed ID: 36173629
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Association of Opioid and Stimulant Use Disorder Diagnoses With Fatal and Nonfatal Overdose Among People With a History of Incarceration.
    Palis H; Gan W; Xavier C; Desai R; Scow M; Sedgemore KO; Greiner L; Nicholls T; Slaunwhite A
    JAMA Netw Open; 2022 Nov; 5(11):e2243653. PubMed ID: 36416821
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Medications for opioid use disorder in state prisons: Perspectives of formerly incarcerated persons.
    Treitler PC; Enich M; Reeves D; Crystal S
    Subst Abus; 2022; 43(1):964-971. PubMed ID: 35420973
    [No Abstract]   [Full Text] [Related]  

  • 29. The association between buprenorphine treatment duration and mortality: a multi-site cohort study of people who discontinued treatment.
    Glanz JM; Binswanger IA; Clarke CL; Nguyen AP; Ford MA; Ray GT; Xu S; Hechter RC; Yarborough BJH; Roblin DW; Ahmedani B; Boscarino JA; Andrade SE; Rosa CL; Campbell CI
    Addiction; 2023 Jan; 118(1):97-107. PubMed ID: 35815386
    [TBL] [Abstract][Full Text] [Related]  

  • 30. An exploratory study of a hands-on naloxone training for rural clinicians and staff.
    Cody SL; Hines CB; Glenn CJ; Sharp-Marbury R; Newman S
    J Nurs Scholarsh; 2023 May; 55(3):599-604. PubMed ID: 36411494
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Drug use patterns and factors related to the use and discontinuation of medications for opioid use disorder in the age of fentanyl: findings from a mixed-methods study of people who use drugs.
    Hughto JMW; Tapper A; Rapisarda SS; Stopka TJ; Palacios WR; Case P; Silcox J; Moyo P; Green TC
    Subst Abuse Treat Prev Policy; 2023 May; 18(1):30. PubMed ID: 37217975
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Suicidal motivations among opioid overdose survivors: Replication and extension.
    Connery HS; Weiss RD; Griffin ML; Trinh CD; Kim J; Rockett IRH; McHugh RK
    Drug Alcohol Depend; 2022 Jun; 235():109437. PubMed ID: 35427980
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Receipt of Telehealth Services, Receipt and Retention of Medications for Opioid Use Disorder, and Medically Treated Overdose Among Medicare Beneficiaries Before and During the COVID-19 Pandemic.
    Jones CM; Shoff C; Hodges K; Blanco C; Losby JL; Ling SM; Compton WM
    JAMA Psychiatry; 2022 Oct; 79(10):981-992. PubMed ID: 36044198
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A qualitative study of emergency department patients who survived an opioid overdose: Perspectives on treatment and unmet needs.
    Hawk K; Grau LE; Fiellin DA; Chawarski M; O'Connor PG; Cirillo N; Breen C; D'Onofrio G
    Acad Emerg Med; 2021 May; 28(5):542-552. PubMed ID: 33346926
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Patterns of clinic switching and continuity of medication for opioid use disorder in a Medicaid-enrolled population.
    Cole ES; Drake C; DiDomenico E; Sharbaugh M; Kim JY; Nagy D; Cochran G; Gordon AJ; Gellad WF; Pringle J; Warwick J; Chang CH; Kmiec J; Kelley D; Donohue JM
    Drug Alcohol Depend; 2021 Apr; 221():108633. PubMed ID: 33631544
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prior use of medications for opioid use disorder in ED patients with opioid overdose: prevalence, misuse and overdose severity.
    Shastry S; Nobel I; Allen LR; Richardson LD; Vidal K; Manini AF
    Am J Emerg Med; 2022 Jan; 51():114-118. PubMed ID: 34735968
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Factors associated with opioid overdose during medication-assisted treatment: How can we identify individuals at risk?
    Au VYO; Rosic T; Sanger N; Hillmer A; Chawar C; Worster A; Marsh DC; Thabane L; Samaan Z
    Harm Reduct J; 2021 Jul; 18(1):71. PubMed ID: 34238301
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Estimated Costs and Outcomes Associated With Use and Nonuse of Medications for Opioid Use Disorder During Incarceration and at Release in Massachusetts.
    Chatterjee A; Weitz M; Savinkina A; Macmadu A; Madushani RWMA; Potee RA; Ryan D; Murphy SM; Walley AY; Linas BP
    JAMA Netw Open; 2023 Apr; 6(4):e237036. PubMed ID: 37058306
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Population-level impact of initiating pharmacotherapy and linking to care people with opioid use disorder at inpatient medically managed withdrawal programs: an effectiveness and cost-effectiveness analysis.
    Savinkina A; Madushani RWMA; Eftekhari Yazdi G; Wang J; Barocas JA; Morgan JR; Assoumou SA; Walley AY; Linas BP; Murphy SM
    Addiction; 2022 Sep; 117(9):2450-2461. PubMed ID: 35315162
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Opioid overdose experiences in a sample of US adolescents and young adults: a thematic analysis.
    Monico LB; Ludwig A; Lertch E; Dionne R; Fishman M; Schwartz RP; Mitchell SG
    Addiction; 2021 Apr; 116(4):865-873. PubMed ID: 32770757
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.